10-K/A: Aimei Health Amends 10-K, Details United Hydrogen Merger Risks

Aimei Health Technology Co., Ltd. filed an amended annual report, providing extensive risk disclosures related to its proposed business combination with PRC-operating United Hydrogen Group Inc. and detailing financial results for 2024.

Summary

• Aimei Health Technology Co., Ltd. (AFJK) is a blank check company (SPAC) incorporated on April 27, 2023, seeking a business combination, primarily targeting small-cap healthcare innovation companies.
• The company entered into a definitive business combination agreement on June 19, 2024, with United Hydrogen Group Inc., a Cayman Islands company with substantial PRC operations.
• The proposed merger involves United Hydrogen becoming a wholly-owned subsidiary of Pubco, and Aimei Health also becoming a wholly-owned subsidiary of Pubco, with Aimei Health shares and rights converting into Pubco Class A Ordinary Shares.
• The deadline for completing a business combination has been extended multiple times, most recently to September 6, 2025, through monthly deposits by the Sponsor and United Hydrogen.
• For the year ended December 31, 2024, the company reported a net income of $2,552,215, primarily from $3,617,001 in interest earned on assets held in the Trust Account, offset by $1,064,786 in formation and operational costs.
• As of December 31, 2024, the Trust Account held $73,784,549, and the company had a working capital deficit of approximately $786,610.
• A material weakness in internal controls over financial reporting was identified as of December 31, 2024, due to inadequate segregation of duties and insufficient written policies.
• United Hydrogen is required to complete filing procedures with the China Securities Regulatory Commission (CSRC) due to its significant PRC operations, and is currently awaiting further review after submitting supplementary materials on August 12, 2024.

Sentiment

Score: 3

Explanation: The filing reveals significant operational and regulatory risks, particularly concerning the PRC-based target and the ongoing CSRC approval process. The identified material weakness in internal controls and the going concern doubt are substantial negatives, outweighing the positive net income derived from trust account interest. While the merger is progressing, the uncertainties create a cautious outlook.

Positives

• Reported a net income of $2,552,215 for the year ended December 31, 2024, driven by interest income from the Trust Account.
• Successfully extended the business combination deadline multiple times, demonstrating commitment to the United Hydrogen merger, now set for September 6, 2025.
• The proposed business combination with United Hydrogen Group Inc. has been unanimously approved by the boards of directors of both companies.
• The company has a clear strategy to target small-cap businesses in biopharmaceutical, medical technology, and diagnostics sectors, leveraging management's experience.

Negatives

• Identified a material weakness in internal controls over financial reporting as of December 31, 2024, due to inadequate segregation of duties and insufficient written policies.
• The company has a working capital deficit of approximately $786,610 as of December 31, 2024.
• The proposed business combination with United Hydrogen is subject to significant legal and operational risks associated with its PRC-based operations, including regulatory uncertainties and potential government intervention.
• United Hydrogen is awaiting further review from the CSRC for its required filing, with no certainty on timing or outcome, which is a condition to closing the business combination.
• The company's ability to continue as a going concern is in substantial doubt if it fails to consummate a business combination within the prescribed period.
• Public shareholders who redeem their shares in connection with the business combination will not have the deferred underwriting commissions ($690,000) deducted from their redemption amount, but these commissions are still payable from the Trust Account upon closing.
• The Sponsor's ability to satisfy indemnity obligations for claims against the Trust Account is uncertain, as its only assets are company securities and it has not reserved for such obligations.

Risks

• Uncertainties regarding the interpretation and enforcement of PRC laws, rules, and regulations, which may materially impact the value of securities.
• Potential for material changes in post-business combination operations or significant depreciation of ordinary share value due to PRC regulatory actions (e.g., cybersecurity reviews, anti-monopoly enforcement, new industry policies).
• Risk that the PRC government may intervene with or influence the combined company's operations at any time to further regulatory, political, and societal goals.
• Uncertainty regarding the timing and outcome of obtaining CSRC filing notice for United Hydrogen, which is a condition to closing the business combination.
• If CSRC or other PRC governmental authorities determine their approval is needed for Aimei Health's IPO, continued U.S. listing, or the business combination, it could lead to approval delays, adverse actions, or sanctions.
• Restrictions on the ability of PRC subsidiaries to pay dividends or transfer net assets to offshore entities due to PRC laws (e.g., distributable profits, statutory reserves, foreign exchange controls).
• Potential for PRC withholding tax up to 10% on dividends paid to overseas shareholders if the combined company is considered a PRC tax resident enterprise.
• Substantial doubt about the company's ability to continue as a going concern if it fails to consummate an initial business combination within the prescribed period, leading to liquidation.
• Intense competition from other entities (SPACs, private equity, venture capital) in identifying and acquiring target businesses.
• Lack of business diversification for an indefinite period after the initial business combination, making success dependent on a single business.
• Potential for conflicts of interest among officers and directors due to multiple business affiliations and fiduciary duties to other entities.
• Risk that the Sponsor may not be able to satisfy its indemnity obligations for claims against the Trust Account if it is required to do so.
• In the event of bankruptcy or winding-up, proceeds in the Trust Account could be subject to creditor claims with higher priority than public shareholders.
• Disclosure controls and procedures were not effective as of December 31, 2024, due to a material weakness in internal controls (inadequate segregation of duties, insufficient written policies).

Future Outlook

The company intends to consummate its initial business combination with United Hydrogen Group Inc. by September 6, 2025, and the Sponsor currently intends to continue depositing funds to extend this deadline up to 24 months from the IPO. Management believes it has sufficient working capital and borrowing capacity to meet anticipated cash needs prior to the initial business combination, though additional financing may be sought. The company will not generate operating revenue until after the completion of its initial business combination.

Management Comments

• We are a blank check company incorporated on April 27, 2023 as a Cayman Islands exempted company and incorporated for the purpose of effecting a merger, share exchange, asset acquisition stock purchase, reorganization, or similar business combination with one or more businesses.
• Our efforts in identifying prospective target businesses will not be limited to a particular geographic region.
• We believe our structure will make us an attractive business combination partner to prospective target businesses.
• Management believes that we will have sufficient working capital and borrowing capacity to meet our anticipated cash needs prior to our initial business combination.
• Management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on our audited financial statements.

Industry Context

As a SPAC targeting healthcare innovation, Aimei Health operates in a competitive landscape with numerous other blank check companies, private equity groups, and venture capital funds. The proposed merger with United Hydrogen, a company with substantial PRC operations, places it within the broader trend of cross-border transactions, but also exposes it to the increasing regulatory scrutiny and evolving legal framework in China, particularly concerning offshore listings and data security. The company's focus on small-cap biopharmaceutical, medical technology, and diagnostics aligns with a growing interest in emerging healthcare technologies, but the inherent risks of early-stage development and regulatory hurdles remain significant.

Comparison to Industry Standards

• The company's status as a blank check company (SPAC) means it has no operating revenue, which is standard for this type of entity prior to a business combination.
• The reported net income is primarily from interest earned on the Trust Account, a typical characteristic of SPACs holding IPO proceeds in low-risk investments.
• The identified material weakness in internal controls over financial reporting, specifically inadequate segregation of duties and insufficient written policies, is a significant concern and falls below best practices for public companies, even smaller reporting companies.
• The extension of the business combination deadline through Sponsor deposits is a common practice for SPACs facing challenges in completing a deal within the initial timeframe, but the repeated extensions highlight potential difficulties.
• The 80% fair market value test for the target business relative to the Trust Account is a standard Nasdaq listing requirement for SPACs.

Management Changes

Corporate Governance

Legal Proceedings

• Not currently a party to any material litigation or other legal proceedings.
• Not aware of any legal proceeding, investigation, or claim with a more than remote possibility of having a material adverse effect.

Related Party Transactions

• Sponsor (Aimei Investment Ltd.) holds 1,905,000 ordinary shares (31.1% of outstanding shares).
• Sponsor and United Hydrogen are jointly providing monthly extension fees for the business combination deadline, evidenced by unsecured promissory notes convertible into private units.
• The company pays the Sponsor $10,000 per month for administrative services, with an unpaid balance of $120,000 as of December 31, 2024.
• A total of $289,780 was due to a related company as of December 31, 2024, for general and administrative services, IPO, and administrative services, including $50,000 for a January 2025 extension payment.
• Working Capital Loans may be provided by the Sponsor, affiliates, or officers/directors, convertible into private units.

Stakeholder Impact

• Shareholders: Face significant uncertainty regarding the completion of the business combination, particularly due to PRC regulatory risks. Public shareholders have redemption rights, but rights holders risk their rights expiring worthless if no business combination. Dilution is possible from new share issuances for the merger or future capital raises.
• Management/Directors: Have potential conflicts of interest due to other affiliations, though they have agreed to present opportunities to Aimei Health first. Their compensation is tied to the completion of a business combination.
• Underwriters: Entitled to a deferred underwriting fee of $690,000 upon the closing of the business combination, which will be forfeited if the business combination is not consummated.
• United Hydrogen: The target company, whose operations are subject to PRC regulatory scrutiny, including the ongoing CSRC filing review, which is a critical condition for the merger.

Next Steps

• Aimei Health to hold an extraordinary general meeting of shareholders to approve the Business Combination Agreement and related proposals.
• United Hydrogen to obtain approval from its shareholders for the Transactions.
• United Hydrogen to continue engaging with the CSRC to obtain the necessary filing notice for its overseas listing.
• Pubco's board of directors and shareholders to adopt and approve an equity incentive plan.
• Pubco to satisfy Nasdaq listing requirements for its ordinary shares.
• The parties to work towards satisfying all other conditions to closing the business combination by September 6, 2025.
• The Sponsor intends to continue depositing funds to extend the business combination deadline up to 24 months from the IPO, if needed.

Key Dates

Recommendation

The company is a SPAC with a proposed business combination that faces significant regulatory and operational hurdles, particularly related to its PRC-based target and the ongoing CSRC approval process. While the company reported net income, this is primarily from interest on its trust account, not operating revenue. The identified material weakness in internal controls and the going concern doubt are serious concerns. However, the unanimous board approval of the merger and the continued efforts to extend the deadline suggest a commitment to closing the deal. Given the high uncertainty and risks, but also the potential upside if the merger is successfully completed, a 'hold' recommendation is appropriate for investors who are already invested or considering a speculative position, acknowledging the significant risks involved. A 'buy' would be too aggressive given the risks, and a 'sell' might be premature given the ongoing efforts to close the merger.

Keywords

SPAC, Business Combination, United Hydrogen, SEC Filing, 10-K/A, Financial Report, PRC Risks, Regulatory Approval, CSRC, Trust Account, Corporate Governance, Internal Controls, Healthcare Innovation, Merger, Acquisition, Blank Check Company, Nasdaq Listing